04:30 PM EDT, 04/30/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price to $42 from $36, 13.6x our 2027 EPS forecast of $3.09, aboveTEVA's historical forward P/E average, justified in our view, by its improving growth prospects. We lower our 2026 EPS estimate to $2.11 from $2.77 to adjust for the Emalex acquisition impact. We keep our 2027 EPS estimate at $3.09. Teva reported a solid Q1, beating expectations, driven by the continued strong performance of its innovative growth engines (AUSTEDO, AJOVY, and UZEDY) which collectively grew 41% and are successfully offsetting the anticipated revenue decline from the loss of exclusivity for the generic REVLIMID. The newly announced $700M Emalex acquisition, expected to close in Q3, is a significant strategic move, and a major positive, in our view. The deal will bring the NDA-ready, first-in-class lead asset Ecopipam to treat Tourette syndrome, which has a significant unmet need, into Teva's neuroscience pipeline. We think the acquisition can accelerate TEVA's shift toward innovative, high-margin products.